Deals· June 12, 2026 · 7 min read
GSK pays $10.6B for Nuvalent: zidesamtinib PDUFA Sept 2026, two NSCLC franchises
By Ran Chen#M&A#Oncology#FDA Approval
Topic
M&A
Mergers and acquisitions, licensing deals, partnership terms, and alliance structures that reshape therapeutic-area competition and pipeline strategy.